Xencor: Buy the Upcoming Data Run — XmAb819 Readout and XmAb942 Interim to Drive Re-rating
Xencor (XNCR) is a speculative buy here. The stock is flashing momentum after a sharp intraday jump to $18.20, and the next six months are loaded with binary clinical events: an XmAb819 presentation and an XmAb942 interim readout expected by the end of 2026. With a market cap near $1.3B, $190M in cash, and recent milestone-driven revenue growth, th…